Your browser doesn't support javascript.
loading
Protocol for characterizing the inhibition of SARS-CoV-2 infection by a protein of interest in cultured cells.
Lai, Xinyuan; Zhuang, Hui; Li, Tong; Xiang, Kuanhui.
Afiliação
  • Lai X; Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China; Peking University-YHLO Joint Laboratory for Molecular Diagnostics of Infectious Diseases, Peking University, Beijing 100191, China.
  • Zhuang H; Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China; Peking University-YHLO Joint Laboratory for Molecular Diagnostics of Infectious Diseases, Peking University, Beijing 100191, China.
  • Li T; Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China; Peking University-YHLO Joint Laboratory for Molecular Diagnostics of Infectious Diseases, Peking University, Beijing 100191, China.
  • Xiang K; Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China; Peking University-YHLO Joint Laboratory for Molecular Diagnostics of Infectious Diseases, Peking University, Beijing 100191, China. Electronic a
STAR Protoc ; 3(4): 101802, 2022 12 16.
Article em En | MEDLINE | ID: mdl-36345374
ABSTRACT
Here, we present a protocol to characterize the antiviral ability of a protein of interest to SARS-CoV-2 infection in cultured cells, using MUC1 as an example. We use SARS-CoV-2 ΔN trVLP system, which utilizes transcription and replication-competent SARS-CoV-2 virus-like particles lacking nucleocapsid gene. We describe the optimized procedure to analyze protein interference of viral attachment and entry into cells, and qRT-PCR-based quantification of viral infection. The protocol can be applied to characterize more antiviral candidates and clarify their functioning stage. For complete details on the use and execution of this protocol, please refer to Lai et al. (2022).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article